Milo Gatti, Ippazio Cosimo Antonazzo, Igor Diemberger, Fabrizio De Ponti, Emanuel Raschi, Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system, «EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY», 2021, 28, Article number: 2047487320915663, pp. 983 - 989 [articolo]Open Access
Gatti, Milo; Giannella, Maddalena; Raschi, Emanuel; Viale, Pierluigi; De Ponti, Fabrizio, Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing, «JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY», 2021, 76, pp. 199 - 205 [articolo]
Raschi E.; Fusaroli M.; Ardizzoni A.; Poluzzi E.; De Ponti F., Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment, «BREAST CANCER RESEARCH AND TREATMENT», 2021, 186, pp. 219 - 227 [articolo]Open Access
Gatti, Milo; Raschi, Emanuel; Moretti, Ugo; Ardizzoni, Andrea; Poluzzi, Elisabetta; Diemberger, Igor, Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase, «VACCINES», 2021, 9, Article number: 19, pp. 1 - 13 [articolo]Open Access
Raschi E.; Fadini G.P.; Diemberger I.; Poluzzi E.; De Ponti F., SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR?, «EXPERT OPINION ON PHARMACOTHERAPY», 2021, 22, pp. 647 - 650 [articolo]
Gatti M.; Bianchin M.; Raschi E.; De Ponti F., Assessing the association between fluoroquinolones and emerging adverse drug reactions raised by regulatory agencies: An umbrella review, «EUROPEAN JOURNAL OF INTERNAL MEDICINE», 2020, 75, pp. 60 - 70 [articolo]
Raschi E.; Caraceni P.; Poluzzi E.; De Ponti F., Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19?, «EXPERT OPINION ON DRUG SAFETY», 2020, 19, pp. 1367 - 1369 [replica/breve intervento]
Raschi E.; Fusaroli M.; Diemberger I.; Poluzzi E., Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance, «DRUG SAFETY», 2020, 43, pp. 1191 - 1194 [articolo]
Gouverneur A.; Lair A.; Arnaud M.; Begaud B.; Raschi E.; Pariente A.; Salvo F., DPP-4 inhibitors and venous thromboembolism: an analysis of the WHO spontaneous reporting database, «THE LANCET DIABETES & ENDOCRINOLOGY», 2020, 8, pp. 365 - 367 [articolo]
Pariente A.; Labat V.; Mansiaux Y.; Salvo F.; Begaud B.; Raschi E.; Faillie J.-L.; Letinier L.; Bezin J., DPP-4 Inhibitors in Combination with Lipid-Lowering Agents and Risk of Serious Muscular Injury: A Nested Case-Control Study in a Nationwide Cohort of Patients with Type 2 Diabetes Mellitus, «DRUG SAFETY», 2020, 43, pp. 767 - 774 [articolo]
Bellesini M.; Bianchin M.; Corradi C.; Donadini M.P.; Raschi E.; Squizzato A., Drug–Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: Looking for Evidence Through a Systematic Review, «CLINICAL DRUG INVESTIGATION», 2020, 40, pp. 1001 - 1008 [articolo]Open Access
Raschi E.; Gatti M.; Gelsomino F.; Ardizzoni A.; Poluzzi E.; De Ponti F., Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance, «TARGETED ONCOLOGY», 2020, 15, pp. 449 - 466 [articolo]Open Access
Gatti M.; Poluzzi E.; De Ponti F.; Raschi E., Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis, «DRUG SAFETY», 2020, 43, pp. 1277 - 1285 [articolo]Open Access
Antonazzo I.C.; Poluzzi E.; Forcesi E.; Salvo F.; Pariente A.; Marchesini G.; De Ponti F.; Raschi E., Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug–drug interactions through the FDA adverse event reporting system, «ACTA DIABETOLOGICA», 2020, 57, pp. 71 - 80 [articolo]
Lunghi C.; Antonazzo I.C.; Burato S.; Raschi E.; Zoffoli V.; Forcesi E.; Sangiorgi E.; Menchetti M.; Roberge P.; Poluzzi E., Prevalence and determinants of long-term utilization of antidepressant drugs: A retrospective cohort study, «NEUROPSYCHIATRIC DISEASE AND TREATMENT», 2020, 16, pp. 1157 - 1170 [articolo]Open Access
